Literature DB >> 12150157

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.

Lucio Luzzatto, Junia V Melo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150157     DOI: 10.1182/blood-2002-05-1578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

Review 1.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Evolutionary dynamics of two related malignant plasma cell lines.

Authors:  David Dingli; Bonnie K Arendt; Zeljko Bajzer; Diane F Jelinek
Journal:  Cell Cycle       Date:  2010-09-15       Impact factor: 4.534

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 4.  Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease.

Authors:  Jorge J Nieva; Peter Kuhn
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

5.  ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

Authors:  Abdalla Awidi; Nidaa Ababneh; Ahmad Magablah; Nazzal Bsoul; Razan Mefleh; Lina Marei; Salah Abbasi
Journal:  Genet Test Mol Biomarkers       Date:  2012-09-25

Review 6.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

7.  K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Authors:  B Douglas Smith; Yvette L Kasamon; Jeanne Kowalski; Christopher Gocke; Kathleen Murphy; Carole B Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; Lu Qin; Christina Chia; Barbara Biedrzycki; Thomas C Harding; Guang Haun Tu; Richard Jones; Kristen Hege; Hyam I Levitsky
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.